Current use of combined hormonal contraception is associated with glucose metabolism disorders in perimenopausal women.

Conclusions: CHC use in perimenopausal women was associated with a significantly increased risk of glucose metabolism disorders. This association should be considered in women with increased metabolic risk. PMID: 33105101 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/33105101?dopt=Abstract

Source: European Journal of Endocrinology - October 28, 2020 Category: Endocrinology Authors: Mosorin ME, Haverinen A, Ollila MM, Nordström T, Jokelainen J, Keinänen-Kiukaanniemi S, Puukka K, Ruokonen A, Auvinen J, Piltonen T, Morin-Papunen L, Tapanainen JS Tags: Eur J Endocrinol Source Type: research